“We look forward to his counsel as an advisor to the company.” “On behalf of the entire Board, I would like to recognize Jerry McMahon for the important role he has played in the financings, business development and growth of Harpoon, and sincerely thank him for his commitment to the company and his leadership during a period where the Harpoon team brought four programs to the clinic and created three T cell platforms,” stated Ron Hunt, member of the Harpoon Therapeutics Board. “I look forward to working alongside the medical and scientific teams to advance Harpoon’s novel immuno-oncology therapeutic modalities through the clinic and ultimately to commercialization, to make a difference in the lives of patients with cancer.” “I am excited to lead Harpoon Therapeutics as its next President and Chief Executive Officer and to champion the company’s clinical programs targeting new breakthrough treatments for cancer,” said Julie Eastland. McMahon has entered into a retirement and transition agreement with Harpoon and will serve as an advisor. Eastland will succeed Jerry McMahon, Ph.D., who has resigned from his position as President and Chief Executive Officer and as a member of the company’s Board of Directors (the “Board”). (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Julie Eastland has been named President and Chief Executive Officer, effective November 8, 2021. 26, 2021 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc.

Scott Myers, Current Member of Harpoon’s Board of Directors Named Chair, Replacing Ron Hunt Who Remains on the Board

Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer Julie Eastland Appointed President and Chief Executive Officer

Harpoon therapeutics stock